UCBJY News and Press, UCB S.A. ADR From 05/10/22

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis PR Newswire Phase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with con...

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS) PR Newswire Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in signific...

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting PR Newswire Scientific presentations illustrate UCB's commitment to addressing unmet needs of people living with a broad range of serious neurological disease...

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) PR Newswire FINTEPLA ® has demonstrated efficacy in the most difficult-to-treat seizure types, 1 ,2 including drop se...

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting PR Newswire Eleven abstracts highlight new data on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis...

UCB (OTCPK:UCBJF) has completed its acquisition of Zogenix (ZGNX), a deal valued at up to $1.9B. The Belgian company acquired Zogenix (ZGNX) for $26 per share plus a milestone-based contingent value right for a potential cash payment of $2 per share. As a result, Zogenix (ZGNX) was delis...

The following slide deck was published by UCB SA in conjunction with their 2021 Q4 earnings call. For further details see: UCB SA 2021 Q4 - Results - Earnings Call Presentation

UCB SA (UCBJF) Q4 2021 Earnings Conference Call February 24, 2022, 8:00 AM ET Company Participants Jean-Christophe Tellier – Chief Executive Officer Sandrine Dufour – Chief Financial Officer Iris Löw-Friedrich – Chief Medical Officer Antje Witte – Vice Preside...

UCB SA press release (OTCPK:UCBJF): FY Non-GAAP EPS of €6.49. Revenue of €5.78B (+8.0% Y/Y). For further details see: UCB SA Non-GAAP EPS of €6.49, revenue of €5.78B

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results - Positive topline results show the Phase 3 RAISE (NCT04115293) zilucoplan trial met primary and all key secondary endpoints in adults with generalized myasthenia gravis - The results show...